IgPro20

Phase 3Biologic

IgPro20 is one of 151 biologic programs targeting Chronic Inflammatory Demyelinating Polyneuropathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

150

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Inflammatory Demyelinating PolyneuropathyActive, not recruiting

ImmunodeficiencyActive, not recruiting

Multiple MyelomaActive, not recruiting

Systemic SclerosisActive, not recruiting

COVID-19Active, not recruiting

Chronic Inflammatory Demyelinating PolyneuropathyPhase 3

Active, not recruiting

ImmunodeficiencyPhase 3

Active, not recruiting

Multiple MyelomaPhase 2

Active, not recruiting

Systemic SclerosisPhase 2

Active, not recruiting

COVID-19Phase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

IgPro20

CSL Behring

Phase 3

1 2

Spikevax

Moderna

Preclinical

21 3

Bnt162b2

BioNTech

Preclinical

29 4

Aimovig

Amgen

Preclinical

1 5

Singulair

AstraZeneca

Preclinical

1 6

Tricor

JJagotec

Preclinical

1 7

Nitrostat

VViatris Specialty LLC

Preclinical

1 8

SARS-COV-2 VACCINE

Moderna

Preclinical

2 9

Aprotinin

Bayer

Preclinical

1 10

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Recruiting

Multiple Myeloma

NCT06976476

Clinical

Trials by Indication[1]

Immunodeficiency2 trials

Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)

Completed· CSL Behring logo

CSL Behring·Phase 3·NCT00719680·21 enrolled

Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

Completed· CSL Behring logo

CSL Behring·Phase 4·NCT03033745·49 enrolled

Chronic Inflammatory Demyelinating Polyneuropathy2 trials

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)

Completed· CSL Behring logo

CSL Behring·Phase 3·NCT01545076·208 enrolled

Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Completed· CSL Behring logo

CSL Behring·Phase 3·NCT02027701·82 enrolled

Immune1 trial

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)

Completed· CSL Behring logo

CSL Behring·Phase 3·NCT00751621·40 enrolled

Multiple Myeloma1 trial

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06976476·100 enrolled

Systemic Sclerosis1 trial

Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)

Completed· CSL Behring logo

CSL Behring·Phase 2·NCT04137224·27 enrolled

1 more indication

COVID-191 trial

Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

Terminated· CSL Behring logo

CSL Behring·Phase 3·NCT06524739·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for IgPro20. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IgPro20 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IgPro20. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSL Behring company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: CSL Behring

IgPro20

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Immunodeficiency2 trials

Chronic Inflammatory Demyelinating Polyneuropathy2 trials

Immune1 trial

Multiple Myeloma1 trial

Systemic Sclerosis1 trial

COVID-191 trial

References

Drug Info

Quick Facts

Related News